Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
Clinical trial NCT06221670 · RECRUITING
Trial details
- NCT number
- NCT06221670
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-20
- Primary completion
- 2026-03-20
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.